JPET Introducing ALZET?ew Model 2006 Pump

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on April 14, 2005; DOI: 10.1124/jpet.105.083964


This Article
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
jpet.105.083964v1
314/1/77    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Miyata, N.
Right arrow Articles by Roman, R. J
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Miyata, N.
Right arrow Articles by Roman, R. J


Received for publication January 20, 2005.
Revised March 29, 2005.
Accepted for publication April 1, 2005.

Beneficial Effects of a new 20-HETE Synthesis Inhibitor, TS-011,on Hemorrhagic and Ischemic Stroke

Noriyuki Miyata 1*, Takayuki Seki 1, Yu Tanaka 1, Tomohiro Omura 1, Kazuo Taniguchi 1, Mariko Doi 1, Kagumi Bandou 1, Shunichi Kametani 1, Masakazu Sato 1, Shigeru Okuyama 1, Liana Cambj-Sapunar 2, David R Harder 2, Richard J Roman 2

1 Taisho Pharmaceutical Co., Ltd. 2 Medical College of Wisconsin

* Address correspondence to: E-mail: noriyuki.miyata{at}po.rd.taisho.co.jp

Abstract

The present study characterized the effects of TS-011 (N-(3-Chloro-4-morpholin-4-yl) phenyl- N'-hydroxyimido formamide), a new selective inhibitor of the synthesis of 20-hydroxyeicosatetrenoic acid (20-HETE), on the metabolism of arachidonic acid by human and rat renal microsomes and the inhibitory effects of this compound on hepatic cytochrome P450 (CYP) enzymes involved in drug metabolism. The effects of TS-011 on the fall in cerebral blood flow following subarachnoid hemorrhage (SAH) and in reducing infarct size in ischemic stroke models were also examined since 20-HETE may contribute to the development of cerebral vasospasm. TS-011 inhibited the synthesis of 20-HETE by human renal microsomes and recombinant CYP4A11 and 4F2, 4F3A and 4F3B enzymes with IC50s around 10-50 nM. It had no effect on the activities of CYP1A, 2C9, 2C19, 2D6 or 3A4 enzymes. TS-011 inhibited the synthesis of 20-HETE by rat renal microsomes with an IC50 of 9.19 nM, and it had no effect on epoxygenase activity at a concentration of 100 µM. TS-011 (0.01-1 mg/kg, i.v.) reversed the fall in cerebral blood flow and the increase in 20-HETE levels in the cerebrospinal fluid of rats after SAH. TS-011 also reduced the infarct volume by 35% following transient ischemic stroke and in intracerebral hemorrhage in rats. Injection of 20-HETE (8 or 12 mg/kg) into the carotid artery produced an infarct similar to that seen in the ischemic stroke model. These studies indicate that blockade of the synthesis of 20-HETE with TS-011 opposes cerebral vasospasm following SAH and reduces infarct size in ischemic models of stroke.


Key words: 20-HETE, Cytochrome P450, Enzyme inhibitor, Stroke, Subarachnoid hemorrhage, TS-011


This article has been cited by other articles:


Home page
Am. J. Physiol. Renal Physiol.Home page
V. Nilakantan, C. Maenpaa, G. Jia, R. J. Roman, and F. Park
20-HETE-mediated cytotoxicity and apoptosis in ischemic kidney epithelial cells
Am J Physiol Renal Physiol, March 1, 2008; 294(3): F562 - F570.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
X. Fang, F. M. Faraci, T. L. Kaduce, S. Harmon, M. L. Modrick, S. Hu, S. A. Moore, J. R. Falck, N. L. Weintraub, and A. A. Spector
20-Hydroxyeicosatetraenoic acid is a potent dilator of mouse basilar artery: role of cyclooxygenase
Am J Physiol Heart Circ Physiol, November 1, 2006; 291(5): H2301 - H2307.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Neuroradiol.Home page
L. Hacein-Bey, D.R. Harder, H.T. Meier, P.N. Varelas, N. Miyata, K.K. Lauer, J.F. Cusick, and R.J. Roman
Reversal of Delayed Vasospasm by TS-011 in the Dual Hemorrhage Dog Model of Subarachnoid Hemorrhage
AJNR Am. J. Neuroradiol., June 1, 2006; 27(6): 1350 - 1354.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
R. J. Roman, K. M. Hoagland, B. Lopez, A. E. Kwitek, M. R. Garrett, J. P. Rapp, J. Lazar, H. J. Jacob, and A. Sarkis
Characterization of blood pressure and renal function in chromosome 5 congenic strains of Dahl S rats
Am J Physiol Renal Physiol, June 1, 2006; 290(6): F1463 - F1471.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
T. Omura, Y. Tanaka, N. Miyata, C. Koizumi, T. Sakurai, M. Fukasawa, K. Hachiuma, T. Minagawa, T. Susumu, S. Yoshida, et al.
Effect of a New Inhibitor of the Synthesis of 20-HETE on Cerebral Ischemia Reperfusion Injury
Stroke, May 1, 2006; 37(5): 1307 - 1313.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
K. Nithipatikom, M. P. Endsley, J. M. Moore, M. A. Isbell, J. R. Falck, W. B. Campbell, and G. J. Gross
Effects of selective inhibition of cytochrome P-450 {omega}-hydroxylases and ischemic preconditioning in myocardial protection
Am J Physiol Heart Circ Physiol, February 1, 2006; 290(2): H500 - H505.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
K. Takeuchi, N. Miyata, M. Renic, D. R. Harder, and R. J. Roman
Hemoglobin, NO, and 20-HETE interactions in mediating cerebral vasoconstriction following SAH
Am J Physiol Regulatory Integrative Comp Physiol, January 1, 2006; 290(1): R84 - R89.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2005 by the American Society for Pharmacology and Experimental Therapeutics.